# OptiBiotix Health plc LPLDL® Exclusive European License Agreement

- Link: https://www.directorstalkinterviews.com/optibiotix-health-plc-lpldl-exclusive-european-license-agreement/412746803
- Published: 2018-03-06T07:13:33+00:00
- Author: Giles Arbor

**OptiBiotix Health plc** (LON:OPTI), a life sciences business developing compounds
to tackle obesity, high cholesterol, diabetes and skin care, announced today that
it has entered into a production and commercialisation agreement with Fine Foods&
Pharmaceuticals N.T.M. S.p.A (“Fine Foods”). The agreement grants Fine Foods an 
exclusive license for the production and supply of five formulations containing 
OptiBiotix’s LPLDL® strain in Europe in return for royalty payments and a commitment
to maximising the financial return for both parties.

Fine Foods is based in Italy and has more than 30 years’ experience in the design,
development and manufacture of customised formulations and presentations for the
pharmaceutical and food supplement industry. With revenues of €120m in 2017, it 
is one of Europe’s largest and fastest growing providers of food supplements and
pharmaceutical products, with full GMP certified production facilities and leading
pharmaceutical companies such as Pfizer, Bayer, Sanofi etc reported as customers
on its website.

Fine Foods has an international reputation and world leading expertise in developing
unique formulations and presentations containing probiotic strains. Under the terms
of the agreement, Fine Foods have an exclusive license to produce and commercialise
five new formulations containing OptiBiotix’s LPLDL®. One for glucose control, one
for reduction of high blood pressure, one for reduction of cholesterol levels and
two for the reduction of cardiovascular risk. These proprietary formulations will
be marketed in innovative presentations including sachets and ‘melt in the mouth’
sticks, to their extensive European network in both the pharmaceutical and food 
supplement industry.

This agreement is another step in a business to business (B2B) strategy of bringing
OptiBiotix’s science together with partner’s expertise and market reach to create
multiple product opportunities to serve consumer healthcare and pharmaceutical markets
around the world.

> **Stephen O’Hara, CEO of OptiBiotix Health Plc, commented:** “We are pleased to
> announce this exclusive license agreement with Fine Foods for the production and
> commercialisation of five new proprietary formulations containing OptiBiotix’s
> LPLDL®. This agreement extends the range of products and presentations containing
> OptiBiotix’s LPLDL® and creates an opportunity to access global pharmaceutical
> markets with an established industry supplier. We chose Fine Foods due to its 
> industry experience, reputation, rapid revenue growth, and impressive client list
> of global customers in both the Pharmaceutical and Food Supplement sectors. We
> believe our strategy of identifying and building partnerships with industry leading
> partners like Fine Foods, provides the best opportunity of rapidly building revenue
> streams, and establishing LPLDL® as a leading global brand.”
> **Giorgio Ferraris, CEO of Fine Foods, commented:** “We are very excited to enter
> this agreement with OptiBiotix, which will allow us to promote specific formulations
> and presentations containing the innovative OptiBiotix’s LPLDL® strain to customers
> active in the growing market segment of Cholesterol and Blood pressure reduction,
> as well as Cardiovascular risk. We believe this a unique opportunity for us to
> expand our commercial presence in the European Food Supplement industry, and has
> the potential to favourably enhance our existing rate of growth over the coming
> years.”

Share on: